Close Menu

NEW YORK (GenomeWeb) – Agilent Technologies announced today that it has been granted expanded use in Europe for its Dako PD-L1 IHC 28-8 pharmDx test, a companion diagnostic for Bristol-Myers Squibb's cancer drug Opdivo (nivolumab).

According to Agilent, the test is now approved for identifying patients with squamous cell carcinoma of the head and neck who are likely to benefit from Opdivo therapy. The test is already approved in Europe for tumor cell PD-L1 expression for non-squamous non-small-cell lung cancer (ns-NSCLC) and melanoma.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.